U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272850) titled 'Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis' on Oct. 02.
Brief Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1% of the world's population [1]. The disease is characterized by synovial membrane inflammation. The impact of RA on quality of life is significant, as it can lead to considerable disability, reduced mobility, and an increased risk of additional health complications [2].
CsDMARDs are the first-line drugs for RA treatment, of which methotrexate (MTX) is the cornerstone drug and monotherapy is recommended as the first choice (3).
However, previou...